Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRIMLJ)

Drug Name
BX-795 Drug Info
Synonyms BX795; BX 795
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10077147
ChEBI ID
CHEMBL91439
CAS Number
CAS 702675-74-9
TTD Drug ID
DMRIMLJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Patented Agent(s)
Approved Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Phosphoinositide dependent protein kinase-1 (PDPK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AR-12 DM4RK6P Lymphoma 2A80-2A86 Phase 1 [4]
L-serine-O-phosphate DMTJ1NH Discovery agent N.A. Investigative [5]
PMID20005102C1 DMMESBW Discovery agent N.A. Investigative [6]
BX-912 DMZA45C Discovery agent N.A. Investigative [2]
PHT-427 DMI96Y3 Discovery agent N.A. Investigative [7]
PF-5177624 DMUOFT0 Solid tumour/cancer 2A00-2F9Z Investigative [8]
GSK-2334470 DM3BI7R Solid tumour/cancer 2A00-2F9Z Investigative [9]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Targeting Checkpoint kinase-1 (CHK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY2603618 DMCXRZF Pancreatic cancer 2C10 Phase 2 [10]
UCN-01 DMUNJZB Non-small-cell lung cancer 2C25.Y Phase 2 [11]
SCH-900776 DM67EMK Solid tumour/cancer 2A00-2F9Z Phase 2 [12]
LY2606368 DM4XMF7 Ovarian cancer 2C73 Phase 2 [13]
LY2880070 DMADEHZ Solid tumour/cancer 2A00-2F9Z Phase 1/2 [14]
RG7741 DMK6P9J Lymphoma 2A80-2A86 Phase 1 [15]
GDC-0425 DMDZ26X Lymphoma 2A80-2A86 Phase 1 [16]
AZD7762 DM1FW0C Solid tumour/cancer 2A00-2F9Z Phase 1 [17]
MK-8776 DMAS1RB Hodgkin lymphoma 2B30 Phase 1 [18]
Diamidothiazole derivative 1 DM02V5Q N. A. N. A. Patented [19]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cyclin-dependent kinase 2 (CDK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [20]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [21]
PHA848125 DMS2Q9G Thymic cancer 2C27 Phase 2 [22]
TG02 DMZFIGQ Anaplastic astrocytoma 2A00.0 Phase 1/2 [23]
NUV-422 DMQJQNT Malignant glioma 2A00.0 Phase 1/2 [24]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [25]
FN-1501 DM7BMD6 Solid tumour/cancer 2A00-2F9Z Phase 1 [26]
AG-024322 DMY4WVK Solid tumour/cancer 2A00-2F9Z Phase 1 [20]
PHA-793887 DM2Y4FG Solid tumour/cancer 2A00-2F9Z Phase 1 [27]
SNS-032 DMEITAS Solid tumour/cancer 2A00-2F9Z Phase 1 [28]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Glycogen synthase kinase-3 beta (GSK-3B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AMO-02 DMJRU3A Myotonic dystrophy 8C71.0 Phase 2/3 [29]
LY2090314 DMTBFE4 Acute myeloid leukaemia 2A60 Phase 2 [30]
Lithium DMZ3OU6 Bipolar disorder 6A60 Phase 2 [31]
Tideglusib DME4LA1 Alzheimer disease 8A20 Phase 2 [32]
9-ING-41 DM57TY3 Myelofibrosis 2A20.2 Phase 2 [33]
Neu-120 DMXKOUC Parkinson disease 8A00.0 Phase 1/2 [34]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [35]
CHIR-99021 DMB8MNU Allergic inflammation 4A80-4A85 Patented [36]
TDZD-8 DMG6Q45 Malignant glioma 2A00.0 Patented [37]
AR-A014418 DMUPN01 Ovarian cancer 2C73 Patented [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [39]
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [40]
Regorafenib DMHSY1I Gastrointestinal stromal tumour 2B5B Approved [41]
Sunitinib DMCBJSR Acute undifferentiated leukemia Approved [42]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [43]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [21]
Pazopanib HCl DM6U9CQ Renal cell carcinoma 2C90 Approved [44]
Fruquintinib DMHOSCQ Colorectal cancer 2B91.Z Approved [45]
Cabozantinib DMIYDT4 Medullary thyroid gland carcinoma Approved [46]
Tivozanib DMUKC5L Renal cell carcinoma 2C90 Approved [47]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Fungal Protein kinase A (Fung ypkA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BALANOL DMDLN9E N. A. N. A. Terminated [48]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X Discovery agent N.A. Investigative [49]
Ro-4396686 DM5DMCH Discovery agent N.A. Investigative [50]
PMID20005102C1 DMMESBW Discovery agent N.A. Investigative [6]
[3H]cAMP DMZRQU7 Discovery agent N.A. Investigative [51]
PMID19364658C33 DMSE1C3 Discovery agent N.A. Investigative [52]
BX-912 DMZA45C Discovery agent N.A. Investigative [2]
chelerythrine DMCP1G9 Discovery agent N.A. Investigative [53]
PMID21742770C1 DME3JMH Discovery agent N.A. Investigative [54]
Rp-adenosine 3',5'-cyclic monophosphothioate triethylamine (Rp-cAMPS) DM1JWGH Discovery agent N.A. Investigative [55]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Daunorubicin DMQUSBT Acute monocytic leukemia Approved [56]
Amlexanox DM0DQM5 Respiratory tract inflammation CA07 Approved [3]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [57]
Acetic Acid, Glacial DM4SJ5Y infection in the ear canal AA0Y Approved [58]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [59]
Testosterone DM7HUNW Hot flushes GA30 Approved [60]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [60]
Motexafin gadolinium DMEJKRF Brain cancer 2A00 Approved [58]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [61]
Melphalan DMOLNHF Hematologic disease 3C0Z Approved [62]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Checkpoint kinase-1 (CHK1) TTTU902 CHK1_HUMAN Inhibitor [2]
Cyclin-dependent kinase 2 (CDK2) TT7HF4W CDK2_HUMAN Inhibitor [2]
Fungal Protein kinase A (Fung ypkA) TTYVI76 Q56921_YEREN Inhibitor [2]
Glycogen synthase kinase-3 beta (GSK-3B) TTRSMW9 GSK3B_HUMAN Inhibitor [2]
Phosphoinositide dependent protein kinase-1 (PDPK1) TT9QBI6 PDPK1_HUMAN Inhibitor [2]
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Inhibitor [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) OT5VYOSM IKKE_HUMAN Gene/Protein Processing [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8006).
2 Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
3 Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J Interferon Cytokine Res. 2015 Mar;35(3):143-56. doi: 10.1089/jir.2014.0038. Epub 2014 Oct 16.
4 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
6 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
7 Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther. 2010 Mar;9(3):706-17.
8 Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells. PLoS One. 2012;7(10):e48402.
9 Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma. Oncogene. 2014 Aug 21;33(34):4330-9.
10 Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.
11 Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening app... J Mol Graph Model. 2009 Sep;28(2):113-30.
12 Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
13 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14 A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3581-3581.
15 National Cancer Institute Drug Dictionary (drug id 730054).
16 Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199).
17 Clinical pipeline report, company report or official report of AstraZeneca (2009).
18 Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. Int J Mol Sci. 2019 Aug 22;20(17):4095.
19 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
20 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
21 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
22 Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
23 Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
24 ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
25 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
26 Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
27 A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
28 Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
29 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
30 Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
31 The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
32 Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
33 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.
34 Company report (Neurim Pharmaceuticals)
35 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
36 Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
37 Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6.
38 Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
39 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
40 Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
41 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
42 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
43 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
44 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
45 Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
46 Clinical pipeline report, company report or official report of Exelixis (2011).
47 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
48 Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry. J Med Chem. 2005 Sep 8;48(18):5613-38. Address;
49 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
50 Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
51 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1694).
52 Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51.
53 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
54 A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.
55 Inhibition of protein kinase A activity interferes with long-term, but not short-term, memory of conditioned taste aversions. Behav Neurosci. 2002 Dec;116(6):1070-4.
56 Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
57 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
58 Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
59 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
60 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
61 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
62 Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.